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BACKGROUND AND PURPOSE
Preclinical pharmacology of 3-iodothyronamine (T1AM), an endogenous derivative of thyroid hormones, indicates that it is a
rapid modulator of rodent metabolism and behaviour. Since T1AM undergoes rapid enzymatic degradation, particularly by
MAO, we hypothesized that the effects of T1AM might be altered by inhibition of MAO.
EXPERIMENTAL APPROACH
We investigated the effects of injecting T1AM (i.c.v.) on (i) feeding behaviour, hyperglycaemia and plasma levels of thyroid
hormones and (ii) T1AM systemic bioavailability, in overnight fasted mice, under control conditions and after pretreatment
with the MAO inhibitor clorgyline. T1AM (1.3, 6.6, 13, 20 and 26 mg·kg-1) or vehicle were injected i.c.v. in fasted male mice
not pretreated or pretreated i.p. with clorgyline (2.5 mg·kg-1). Glycaemia was measured by a glucorefractometer, plasma
triiodothyronine (fT3) by a chemiluminescent immunometric assay, c-fos activation immunohistochemically and plasma T1AM
by HPLC coupled to tandem-MS.
KEY RESULTS
T1AM, 1.3 mg·kg-1, produced a hypophagic effect (-24% vs. control) and reduced c-fos activation. This dose showed systemic
bioavailability (0.12% of injected dose), raised plasma glucose levels and reduced peripheral insulin sensitivity (-33% vs.
control) and plasma fT3 levels. These effects were not linearly related to the dose injected. Clorgyline pretreatment strongly
increased the systemic bioavailability of T1AM and prevented the hyperglycaemia and reduction in fT3 induced by T1AM.
CONCLUSIONS AND IMPLICATIONS
T1AM induces central and peripheral effects including hyperglycaemia and a reduction in plasma fT3 levels in fasted mice.
These effects critically depend on the concentration of T1AM or its metabolites in target organs.
Abbreviations
fT3, triiodothyronine; fT4, thyroxine; NPY, neuropeptide Y; T1AM, 3-iodothyronamine; TARR, trace amine-associated
receptor; TSH, thyroid stimulating hormone
Introduction
3-Iodothyronamine (T1AM) is an endogenous primary amine
related to thyroid hormones (Scanlan et al., 2004; Phiel et al.,
2011). T1AM circulates in healthy rodents and humans but is
also present in most tissues, and the highest concentrations
in rats occur in the liver and the brain (Saba et al., 2010;
Hoefig et al., 2011). The physiological role of T1AM is still
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under investigation, and recent data suggest that it may have
metabolic and endocrine effects (Hoefig et al., 2011). Differ-
ent pharmacological responses have been elicited after
administration of exogenous T1AM. T1AM injected i.c.v. into
rodents rapidly induces metabolic effects, which are not lin-
early related to the dosage and are dependent on the animal
species and route of administration. In particular, Klieverik
et al. (2009) observed that i.c.v. injection of T1AM
(0.5 mg·kg-1) in rats rapidly induced hyperglycaemia, whereas
after i.p. administration of T1AM, the hyperglycaemia
observed and was also associated with decreased plasma
levels of triiodothyronine (fT3).
Dhillo et al. (2009) reported a transient increase in food
intake in rats and mice treated with T1AM (1.2 and
4 nmol·kg-1, respectively), an effect that was not conserved at
lower and higher doses. The same authors demonstrated that
exposure of hypothalamic slices to T1AM in vitro induced
neuropeptide Y (NPY) release, suggesting that this potent
orexigenic peptide is involved in the hyperphagic effect.
However, in a recent preliminary study, Hettinger et al. (2010)
observed that chronic systemic administration of T1AM
(31 mg·kg-1·day-1) reduced food intake in mice.
These discrepancies might derive, at least in part, from the
complex metabolism of T1AM, that includes amine oxidation
by mitochondrial (MAO) and/or semicarbazide-sensitive
amine oxidases, yielding metabolites that have functional
effects, if any, that are still unknown. Rapid amine degrada-
tion might contribute to the bell-shaped dose–response rela-
tionships observed following T1AM treatment of rodents. In
addition, T1AM has been found to interfere with the response
to other biogenic amines (Snead et al., 2007).
The molecular target(s) responsible for T1AM metabolic
effects are largely unknown. In vitro studies provided evidence
that T1AM can activate amine GPCRs with high affinity,
including trace amine-associated receptors (TAARs) (Scanlan
et al., 2004; Zucchi et al., 2006) and possibly a2-adrenoceptors
(Regard et al., 2007). Other putative molecular targets are
membrane transporters, including vesicular monoamine
transporter 2, which suggests a possible neuromodulatory
role for T1AM (Snead et al., 2007; Ianculescu et al., 2009).
Recently, functional evidence of mitochondrial targets has
been obtained (Venditti et al., 2011).
The present investigation was planned to explore the
consequences of injecting T1AM (from 1.3 to 26 mg·kg-1,
i.c.v.) on feeding behaviour, hyperglycaemia and plasma
levels of thyroid hormones in overnight fasted mice, under
control conditions and after pretreatment with clorgyline, an
inhibitor of MAO activity. Moreover, we also aimed to verify
whether T1AM injected i.c.v. had any systemic bioavailabil-
ity. The rationale for using fasting animals is that fasting
causes activation of hypothalamic orexigenic systems
(Coppola et al., 2007) and pancreatic secretion, making it
easier to detect a potential inhibitory effect.
Methods
Animals
Male mice (CD1 strain; 25.2  3.2 g mean weight) from
Harlan-Nossan (Italy) were used. Five mice were housed per
cage. The cages were placed in the experimental room 24 h
before the test for adaptation and, unless otherwise stated,
the mice were deprived of food (fasted) overnight before the
experiments. The animals were kept at 23  1°C with a 12 h
light–dark cycle (light on at 07h00min) and were fed a stan-
dard laboratory diet with water ad libitum.
All animal care and experimental procedures were carried
out in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) for experimen-
tal animal care. All efforts were made to minimize animal
suffering and to reduce the number of animals used.
I.c.v. injection technique
I.c.v. administration was performed under light ether anaes-
thesia according to the method described by Haley and
McCormick (1957) with certain modifications. The depth of
anesthesia was checked by monitoring respiratory rate
(which was reduced within 2 min) and testing the lack of
pain response to gentle pressure on the hind paws. The head
of the anaesthetized mouse was grasped firmly, and the
needle of a 10 mL microsyringe was inserted perpendicularly
2 mm through the skull into the brain. Ten microlitres of
solution were then injected slowly, in 20 s, into a lateral
ventricle. The injection site was 1 mm to the left from the
midpoint on a line drawn through to the anterior base of the
ears. Immediately after needle removal, the animal remained
quiet for approximately 1 min and then resumed its normal
activity. To ascertain that solutions were administered exactly
into the cerebral ventricle, some mice were injected with
10 mL of diluted 1:10 India ink, and their brains were exam-
ined macroscopically after sectioning, showing that 95% of
injections were correct.
Evaluation of food consumption
Mice (five per cage) were deprived of food for 16 h (from 17 h
to 09 h), but water was available ad libitum.
A weighed amount of food (standard laboratory pellets)
was then given, and the amount consumed (evaluated as the
difference between the original amount and the food left in
the cage without littermate, including spillage) was measured
at 30, 60, 90, 120 min after i.c.v. (second ventricle) adminis-
tration to anaesthetized mice of 10 mL of 0.5% dimethyl sul-
foxide w v-1 in saline solution (vehicle) or T1AM (1.3, 6.6,
13.2, 20 and 26 mg·kg-1 prepared in vehicle), with an accuracy
of 0.1 g. Both the T1AM and vehicle-injected mice were
treated i.p. with saline solution or clorgyline (2.5 mg·kg-1;
Sigma-Aldrich, St Louis, MO, USA) 30 min before the T1AM
i.c.v. injections. The results presented are the mean  SEM of
two experiments; in each one 10 animals were used for each
injection.
c-fos determination
Mice fasted for 16 h were pretreated with saline i.p., 30 min
before an injection of T1AM 1.3 mg·kg-1 (n = 3), T1AM
20 mg·kg-1 (n = 3) or vehicle i.c.v. (n = 3) under ether anaes-
thesia, as described above. Animals were then killed by
decapitation, within 60 min after i.c.v. injection. The skull
was opened with scissors and the brain surface was cooled
down, by exposing it to liquid nitrogen vapours for 1–2 s in
situ. The brain was then removed and the forebrain was
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divided into two parts: the cortex and the diencephalon. The
hypothalamus was quickly separated from the thalamus,
flash-frozen at -80°C and embedded in Killik cryostat embed-
ding medium (Bio-Optica, Milan Italy). Cryosections, 10 mm
thick, were collected on polylysine-coated slides and fixed in
paraformaldehyde vapour for 10 min.
In order to quench endogenous peroxidase activity, the
slides were treated with 3% H2O2 in H2O and then pre-
incubated with 1% BSA (Sigma Aldrich, Milan, Italy) in PBS
(pH 7.8) for 20 min to saturate non-specific sites. Then, the
slides were incubated overnight at 4°C with rabbit polyclonal
anti-c-fos antibodies (Santa Cruz Biotechnology, CA, USA) at
a final dilution of 1:100. In the negative controls carried out,
the primary antibody was omitted. Immunoreactivity was
revealed by goat anti-rabbit IgG conjugated with biotin
(Vector Lab, Burlingame, CA, USA) at a final dilution of
1:1000 followed by incubation with ABC complex (Vector
Lab) and then with Sigma FAST 3-3′- diaminobenzidine
(Sigma Aldrich).
Staining was performed in a single session, to minimize
artificial differences. Photomicrographs were randomly taken
using a digital photomicroscopy apparatus (Jenoptik, Jena,
Germany) with a ¥25 objective. Each microscopic field corre-
sponded to a test area of 24.2 mm2. The optical density of c-fos
immunostained tissue was measured on the digitized images
(10 per animal) using the Image J image analysis programme
(by the National Institute of Health, Bethesda, MD, USA).
After evaluation of the optical density, sections were coun-
terstained with haematoxylin for 90 s.
Glycaemia and collection of samples for
T1AM plasma level determination
Blood samples were collected from the tail vein of 16 h fasted
mice pretreated i.p. with clorgyline (2.5 mg·kg-1) or with
saline, 30 min before i.c.v. vehicle (n = 15) or T1AM1.3 (n = 15)
or 20 mg·kg-1 (n = 15). Five mice in each group were killed by
decapitation 30 min after T1AM injection to collect the blood
and the brains in order to measure plasma T1AM tissue levels.
In another set of experiments, glycaemia was monitored
in the blood collected from the tail vein of 4 h (from 8 h to
12 h) fasted mice who had received T1AM (1.3 mg·kg-1 i.c.v)
and saline (i.p.), or T1AM (1.3 mg·kg-1 i.c.v) and exenatide
(0.25 mg·mL-1 i.p.), or vehicle i.c.v and exenatide
(0.25 mg·mL-1 i.p.) (n = 5 in each group). Glycaemia was
evaluated by a glucorefractometer at 0, 15, 30 and 60 min
after the i.c.v. injections.
T1AM plasma and brain levels
T1AM levels were measured in plasma and brain samples by
HPLC coupled to tandem-MS, as described previously (Saba
et al., 2010).
Insulin tolerance test
An i.p. insulin tolerance test was performed in 4 h fasted mice
(from 8 h to 12 h), a condition chosen to avoid hypoglycae-
mia following insulin treatment.
Three experimental groups were considered (n = 5 mice
per group): one group was injected i.c.v. with vehicle, one
with 1.3 mg·kg-1 T1AM and one with T1AM 20 mg·kg-1 T1AM
under light ether anaesthesia. All these animals received
insulin (1 U·kg-1 Humulin R Regular, Ely Lilly, Indianapolis,
IN, USA) i.p. 10 min after the i.c.v. injection.
Small blood samples from the lateral tail vein were col-
lected to measure glycaemic levels at time 0, 15, 30, 60, 90
and 120 min after i.p. insulin injection. A glucose solution
(33% w·v-1) was prepared in order to correct symptomatic
hypoglycaemia. Results are shown as glucose concentration
(mg·L-1) and as the difference from the baseline value.
Plasma levels of thyroid hormones
To evaluate free plasma triiodothyronine (fT3), thyroxine
(fT4) and thyroid stimulating hormone (TSH) levels, three
sets of experiments were performed on 4 h fasted mice (n = 5
mice in each experimental group):
Exp. 1: mice pretreated with saline i.p., 30 min before
i.c.v. injection with vehicle, 1.3 mg·kg-1 T1AM, or
20 mg·kg-1 T1AM.
Exp. 2: mice pretreated with clorgyline (2.5 mg·kg-1) i.p,
30 min before i.c.v. injection with vehicle or 1.3 mg·kg-1
T1AM.
Exp. 3: mice treated with exenatide (0.25 mg·mL-1) i.p., 30
min before i.c.v. injection of vehicle or 1.3 mg·kg-1 T1AM.
All the animals were killed by decapitation within 60 min
after i.c.v. injections. The blood was collected and centrifuged
at 3000¥ g for 20 min at room temperature to prepare plasma.
Circulating fT3, fT4 and TSH levels were quantified in
100 mL of mouse plasma, by a solid-phase, two-site chemilu-
minescent immunometric assay (Immunolite 2000; Siemens
Corp., Tarrytown, NY, USA). The manufacturer’s reference
limit were 2.3–4.2 pg·mL-1, 0.5 nmol·L-1 and 0.40 mU·L-1,
respectively, fT3, fT4 and TSH. The assay was validated by
unchanged plasma fT3 and fT4 levels recovered over 1:10
plasma. Intra-assay variability was in the range of 8%.
Statistical analysis
Data are expressed as mean  SEM of independent experi-
ments. Statistical analysis was performed by one-way ANOVA,
followed by Student–Newman–Keuls multiple comparison
post hoc test; the threshold of statistical significance was set at
P < 0.05. Data analysis was performed by GraphPad Prism 5.0
statistical program (GraphPad software, San Diego, CA, USA).
Results
T1AM injected i.c.v. in fasted mice induced
hypophagia and hyperphagia: the effect of
clorgyline pretreatment
Increasing doses of T1AM (1.3, 6.5, 13, 20 and 20 mg·kg-1; n =
10 mice for each dose) produced opposite effects on feeding.
In particular, after 120 min, the total amount of food eaten (g
per mouse) by mice receiving 1.3 and 20 mg·kg-1 T1AM was
significantly (P < 0.05) lower (2.74  0.084) and higher (3.83
 0.02), respectively, than the control value (3.29  0.08).
The hypophagic effect of T1AM 1.3 mg·kg-1 derived from
increased satiety occurring within the first 30 min after injec-
tion. In fact, mice injected with T1AM 1.3 mg·kg-1 almost
stopped feeding within the first 30 min, while those injected
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with T1AM 20 mg·kg-1 and with vehicle reached satiety within
60 min. Both effects on feeding were significantly different
from vehicle-injected mice 60 min after injection, and the
difference persisted for the whole duration of the experiment
(120 min).
With T1AM doses of 6.5, 13 or 26 mg·kg-1, a slight increase
in feeding versus vehicle- injected mice was observed, but the
effect did not reach the threshold of statistical significance
(data not shown). T1AM effects on feeding behaviour of
fasted mice did not show a linear dose–effect relationship but,
rather, a biphasic response.
In mice pretreated with clorgyline (2.5 mg·kg-1; Ilani et al.,
2000), the hypophagic effect of T1AM 1.3 mmol·kg-1 was con-
served, and it reached the threshold of statistical difference
versus vehicle-injectedmicewithin the first 30 min after injec-
tion (Figure 1B), while satiety occurred within 60 min. Con-
versely, the hyperphagia induced by 20 mmol·kg-1 T1AM was
completely prevented (Figure 1B). Clorgyline did not affect
the food intake of fasted mice injected with vehicle.
All further investigations were performed using T1AM
dosages able to produce effects on feeding, namely 1.3 and
20 mmol·kg-1.
Hypothalamic c-fos expression in fasted mice
is reduced by T1AM injection
In the hypothalamus of 16 h fasted mice injected i.c.v. with
vehicle, strong c-fos activation was observed. A significantly
lower activation was found in hypothalamic slices derived
from mice that had been injected i.c.v. with either 1.3 or
20 mg·kg-1 T1AM (Figure 2).
T1AM injected i.c.v. presented
systemic bioavailability
T1AM given i.c.v. showed systemic bioavailability, suggesting
spillover from the central nervous system. As shown in
Table 1, the percentage of amine recovered was around 0.2%
of the amount injected at both the low and the high dose (1.3
and 20 mg·kg-1, respectively). This result suggested that only a
small amount of the injected T1AM can reach the periphery
and that the mechanism responsible for its transport into the
blood is not simple diffusion but rather a carrier-mediated
mechanism. In mice with MAO blockade, systemic bioavail-
ability of endogenous and pharmacological injected T1AM
increased markedly (Table 1). Under these experimental
Figure 1
The i.c.v. administration of T1AM resulted in hypo- and hyperphagia: the effect of clorgyline pretreatment. Mice fasted for 16 h were pretreated
i.p. with saline solution (A) or with clorgyline 2.5 mg·kg-1 (B). After 30 min, mice (n = 10) were injected i.c.v. with vehicle or with T1AM (from
1.3 to 26 mg kg-1; n = 10 mice for each dose), mice were then allowed food and water ad libitum. The amount of food consumed after 30, 60,
90 and 120 min following T1AM or vehicle injection was evaluated as described in the Methods section. Results are expressed as means  SEM
of two experiments. Clorgyline pretreatment did not affect mice feeding behaviour compared to vehicle-injected mice. *P < 0.05 vs. vehicle.
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conditions, the bioavailability of 1.3 mg·kg-1 T1AM increased
only twice, while with 20 mg·kg-1 T1AM, a 40-fold increase
was observed. The yield of T1AM recovery was calculated in a
volume of 1.5 mL of blood for each mouse (Lee and Blaufox,
1985).
T1AM injected i.c.v. rapidly induced
hyperglycaemia: the effect of
clorgyline pretreatment
Despite opposite effects on feeding, both 1.3 and 20 mg·kg-1
T1AM rapidly (within 15 min) induced hyperglycaemia
(Figure 3) in fasted mice, which persisted up to 60 min after
injection (data not shown).
Clorgyline (2.5 mg·kg-1) pretreatment strongly affected
T1AM-induced hyperglycaemia, since both doses of T1AM
became ineffective (Figure 3). Interestingly, 60 min after the
administration of 20 mg·kg-1 T1AM, the animals actually
showed very low levels of glycaemia (47.7  5.6 mg·dL-1).
A
B
Figure 2
T1AM reduces c-fos expression in the hypothalamus of fasted mice. Hypothalamus was isolated from the brain of animals killed within 60 min after
i.c.v. injection of vehicle (Veh.) or T1AM 1.3 and 20 mg kg-1 . Sections were prepared for immunohistochemistry (A) and evaluation of optical
density (B) was performed as described in the Methods section. *P < 0.05 vs. vehicle.
Table 1
T1AM levels in the systemic circulation
T1AM (mg·kg-1) pmol·mL-1 Total pmol Yield (%)
Vehicle ND
1.3 0.19 0.28 0.215
20 1.5 2.25 0.15
Veh +clorgyline 0.05 0.082 0.082
1.3+clorgyline 0.35 0.52 0.52
20+clorgyline 57.05 85.58 5.7
T1AM plasma levels were assayed as described in the Methods
section following i.c.v. injection of vehicle or 1.3 and
20 mg·kg-1.
Results were obtained from pooled plasma samples (five mice for
each group) collected from 16 h-fasted mice.Veh, vehicle. The
dose of clorgyline used was 2.5 mg·kg-1.
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T1AM-induced hyperglycaemia increased
insulin resistance
We also tested whether the hyperglycaemia induced by T1AM
was associated with a reduction in insulin peripheral sensi-
tivity. To do this, we performed an i.p. insulin tolerance test
in mice deprived of food for 4 h, as described in the Methods
section. The condition of 4 h fasting was chosen to avoid
severe hypoglycaemia. Peripheral insulin sensitivity was sig-
nificantly reduced after the injection of 1.3 mg·kg-1 T1AM,
while at the dose of 20 mg·kg-1, the response to insulin was
not different from that obtained in vehicle-injected animals
(Figure 4A and B).
T1AM 1.3 mg·kg-1-induced hyperglycaemia
was prevented by exenatide treatment
In order to evaluate whether the hyperglycaemia induced by
1.3 mg·kg-1 T1AM involved glucagon secretion, we repeated
the previous experiments in mice treated i.p. with exenatide
(0.25 mg·mL-1; Byetta, Ely Lilly; n = 5), a glucagon-like
peptide-1 analogue which prevents glucagon release with a
low risk of hypoglycaemia. As shown in Figure 5, the hyper-
glycaemia induced by T1AM (1.3 mg·kg-1) was prevented in
mice treated with exenatide.
T1AM injection reduced fT3 plasma
levels: the effect of exenatide and
clorgyline pretreatment
Subsequently, we verified whether the T1AM doses active on
food intake and on glucose homeostasis were able to modify
Figure 3
T1AM injected i.c.v. increases plasma glycaemia: the effect of clor-
gyline pretreatment. The blood was collected from the tail vein of
two groups (n = 5 each) of mice (fasted for 16 h) pretreated i.p. with
clorgyline (2.5 mg·kg-1) or with saline, 30 min before i.c.v. injection
of vehicle or T1AM 1.3 and 20 mg kg-1 . Glycaemia was evaluated by
a glucorefractometer at 0, 15, 30 and 60 min after i.c.v. injections.
Results are the means  SEM of two experiments carried out on five
mice for each experimental setting. The value of glycaemia measured
15 min after T1AM injection is shown. *P < 0.05 vs. vehicle i.c.v and
saline i.p; § and °P < 0.05 vs. T1AM 1.3 and 20 mg kg-1, respectively,
in the absence of clorgyline pretreatment.
A
B
Figure 4
T1AM 1.3 mg·kg-1reduces peripheral insulin sensitivity. Fifteen mice
fasted for 4 h, were divided into three groups (five mice each). One
group was injected i.c.v. with T1AM 1.3 mg kg-1, one with T1AM
20 mg kg-1, and both i.p. with insulin (1 U·kg-1). The remaining
group was injected i.c.v. with vehicle and i.p. with insulin (1 U·kg-1).
Small blood samples from the lateral tail vein were collected to
measure glycaemic levels at 0, 15, 30, 60, 90 and 120 min after i.p.
insulin treatment. Results are shown as glucose levels (mg·L-1) and as
the difference between glycaemia at one time point and the value at
T = 0 (D glycaemia mg·L-1). Results represent the means  SEM of
the values of two experiments carried on five mice for each time
point. *P < 0.05 vs. vehicle.
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plasma T3 levels. Following an injection of 1.3 mg·kg-1 T1AM,
the fT3 plasma concentration was significantly reduced, from
2.34  0.09 in vehicle treated mice to 1.82  0.11 pmol L-1
(P < 0.05 vs. vehicle), while no change was observed following
20 mg kg-1 T1AM (2.37  0.20 pmol L-1). This T1AM effect on
fT3 was not detected in mice treated with exenatide i.p. or in
those pretreated with clorgyline 30 min before T1AM injec-
tion (2.41  0.09 and 2.20  0.18 pmol L-1, respectively).
Plasma fT4 levels averaged 33.05  1.55 pmol·L-1 in the
vehicle group, and were not significantly modified in T1AM
1.3 and 20 mg·kg-1 injected mice (30.67  1.96 and 31.66 
3.75, respectively) as well as in exenatide (37.00  2.88) and
clorgyline (29.66  1.45) i.p. treated mice. TSH levels mea-
sured in vehicle and T1AM-injected mice stabilized closed to
the limit of the method (4  2 mU·mL-1).
Discussion
We observed that i.c.v. injection of 1.3 mg·kg-1 T1AM in fasted
mice produced central and peripheral effects, including
hypophagia, hyperglycaemia and a reduction in plasma fT3
levels. All these effects were not linearly dependent on T1AM
dosage. In fact, the hypophagia vanished at doses higher than
1.3 mg·kg-1, and it was replaced by hyperphagia at 20 mg·kg-1.
The latter dose was also ineffective on plasma fT3 levels. This
biphasic response might account for the different results
reported in the literature in ad libitum fed mice (Dhillo et al.,
2009; Hettinger et al., 2010).
It is well known that fasting induces c-fos expression and
that activation of NPY-ergic neurons plays an important role
in this response (Yang et al., 1995; Becskei et al., 2010).
Accordingly, in the hypothalamus of our fasted mice, we
observed a strong positivity for c-fos immunostaining, which
was reduced by injecting T1AM (either 1.3 or 20 mg·kg-1). This
is consistent with the proposed anti-adrenergic features of
T1AM, and might be due either to TAAR1-mediated inhibi-
tion of cAMP production, or to activation of presynaptic
a2-adrenoceptors (Gompfa et al., 2010), causing a reduction
of c-fos activation and of the ‘functional’ anorexigenic effect
resulting from fasting-induced NPY overflow (Murphy et al.,
2009). Instead, the hyperphagia observed with 20 mg·kg-1
T1AM could be the consequence of desensitization of
a2-drenergic receptors located on NPY-ergic neurons or of
a2-mediated reduction of the release of some anorexigenic
signals, including catecholamines and/or 5-HT. Both mecha-
nisms could occur simultaneously but, depending on T1AM
dosage, one would prevail over the other.
After clorgyline pretreatment, the hypophagic effect was
preserved, while hyperphagia was prevented. This observa-
tion might imply that: (i) increased adrenergic drive due to
amine oxidase inhibition can overcome the anti-adrenergic
effect of T1AM; (ii) since T1AM itself is a substrate of amine
oxidases, T1AM catabolites like 3-iodoacetic acid or thyroace-
tic acid might be involved in neuronal effects; or (iii)
increased T1AM levels might induce a rapid desensitization of
the target (s).
Our finding that T1AM injected i.c.v. had systemic bio-
availability is novel and interesting. Even though we only
tested two T1AM doses, our results suggest that T1AM entry
into the blood is mediated by a transporter rather than rep-
resenting simple diffusion. Whatever the mechanism may be,
the occurrence of T1AM in the systemic circulation suggests
that peripheral effects should be expected following i.c.v.
T1AM administration. Systemic bioavailability increased
markedly under conditions of MAO inhibition, indicating
intracellular deamination as a prominent metabolic pathway
of T1AM. Therefore, in the presence of the MAO inhibitor
clorgyline, T1AM central and peripheral levels increase, mim-
icking the effects of higher T1AM doses. This is another
possible reason why after clorgyline pretreatment, 20 mg·kg-1
T1AM was ineffective at modifying feeding as seen with
higher doses of T1AM (26 mg·kg-1) in the absence of
clorgyline.
Figure 5
Exenatide treatment prevented T1AM (1.3 mg kg-1)-induced increase in plasma glycaemia. Glycaemia was also monitored in the blood collected
from the tail vein of 4 h fasted mice (n = 5 mice for each injection) treated as described in the Methods section. Mice received T1AM 1.3 mg·kg-1
i.c.v and saline i.p., or T1AM 1.3 mg·kg-1 i.c.v and exenatide (0.25 mg·mL-1) i.p., or vehicle (Veh.) i.c.v and exenatide (0.25 mg·mL-1) i.p. Results
represent the means  SEM of the values of two experiments carried out on five mice for each time point. *P < 0.05 vs. basal glycaemia level
(T = 0); §P < 0.05 vs. T1AM in the absence of exenatide.
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While T1AM has been detected in rat and human serum
(Saba et al., 2010; Hoefig et al., 2011), endogenous T1AM was
not detectable in mouse plasma. This is probably due to the
fact that our extraction procedure is much less effective in
plasma than in serum (Saba et al., unpublished results); the
endogenous plasma concentration is probably below the
limit of detection.
Peripheral actions are the likely cause for the effects of
T1AM on plasma glucose, since, in pancreatic cells, T1AM
has been reported to induce glucagon secretion and
decrease insulin secretion (Regard et al., 2007). The hyperg-
lycaemic effect of 1.3 mg·kg-1 was associated with a transient
reduction in peripheral insulin sensitivity, and was pre-
vented by exenatide, suggesting a major role for glucagon
secretion, while at 20 mg·kg-1, reduced insulin secretion
might also be involved. Notably, our results indicate that
T1AM has a high affinity for the pancreas, and hypergly-
caemia was achieved at plasma concentrations of T1AM in
the order of 0.35 nM. With regard to the hyperphagic effect,
T1AM was unable to produce hyperglycaemia in mice pre-
treated with clorgyline. Again, this might imply that
increased sympathetic drive counteracting the effect of
T1AM depends on glucagon release, since a biphasic effect
of T1AM on insulin secretion has been described: low con-
centrations inhibited insulin secretion, possibly through
a2-adrenoceptors, but high concentration had a stimulating
effect, possibly mediated by TAAR1 (Regard et al., 2007;
Winzell and Ahren, 2007). An alternative possibility is that
glucagon release may be stimulated by T1AM catabolites
produced through oxidative deamination. The latter
hypothesis seems unlikely, however, since such derivatives
could not be detected in plasma, at least within limits of
our assay.
T1AM (1.3 mg·kg-1) also reduced systemic fT3 levels. This
effect was prevented by exenatide, supporting a role for glu-
cagon. Consistent with this hypothesis, inhibition of liver
deiodinase activities by glucagon has been reported (Mitchell
and Raza, 1986; Kabadi and Premachandra, 1988). No change
in fT3 was observed after 20 mg·kg-1 T1AM, which might be
explained by increased insulin secretion, since insulin is
known to stimulate liver deiodinase activities (Sato et al.,
1984). Another hint regarding the role of the pancreas is the
observation that changes in fT3 were prevented by clorgyline
pretreatment. Glucagon might represent the factor linking T3
plasma levels with hyperglycaemia and might even contrib-
ute to changes in mice feeding patterns (Valassi et al., 2008).
In summary, we have demonstrated that a single low
dose of T1AM is able to decrease mice feeding and plasma
fT3 levels while increasing plasma glucose and raising insulin
resistance. T1AM appears to be a potent amine stimulating
the CNS, the pancreas and, in turn, the liver where it might
affect fT3 production and/or degradation. The picture we
have drawn indicates that T1AM is a molecule with a very
interesting non-genomic profile. Since these effects cluster in
endocrine disorders, including thyroid dysfunctions and dia-
betes, the assay of tissue and plasma T1AM levels in experi-
mental models of thyroid diseases and diabetes might open
new paths for diagnosis and/or therapy of such diseases. In
addition, prevention of the metabolic effects of T1AM might
be included among the therapeutic, or side effects, of MAO
inhibitors.
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